Smarter oncology second opinion — AI-powered, expert-reviewed, using your existing NGS report.
Read More
Over the past decade, precision oncology has changed how cancer is diagnosed and treated. Tests like next-generation sequencing (NGS) can now look inside a tumor and identify genetic changes that may be driving the disease. In many cases, this has opened the door to targeted therapies that would not have been considered before.
But in everyday practice, something doesn’t always add up. Patients go through advanced testing, receive a detailed report, and still walk away without a clear treatment plan. The issue is not that the data is missing. The issue is that the data is difficult to fully interpret.
Genomic testing was designed to answer a very important question: what is driving this cancer at a biological level?
Instead of treating all cancers of the same type the same way, it allows doctors to look for specific mutations or biomarkers that may respond to certain therapies. In some cases, this has led to highly targeted treatments that are more effective and sometimes better tolerated. Tumor sequencing has made it possible to:
In cancers like lung cancer and melanoma, this approach has made a real difference. It has opened the door to treatments that were not available just a few years ago.
So the value of genomic testing is not in question. But in practice, what becomes clear is that identifying these changes is only the beginning.
It is not uncommon for patients to receive a genomic report that raises more questions than it answers. There may be several mutations listed, but no clear recommendation. Or the report may say there are “no actionable findings,” even though the tumor clearly has genetic changes. In some cases, multiple treatment options are mentioned, but there is no clear guidance on which one makes the most sense.
From a patient’s perspective, this can feel like going through a detailed test and still not knowing what the result really means.
From a clinical perspective, the situation is more nuanced. The information is there, but it hasn’t been fully translated into a decision.
When you receive a genomic report, it often presents your cancer as a list of mutations. It’s natural to read it that way, one finding at a time, each with its own label and possible treatment. But that’s not how cancer behaves in the body.
In reality, these changes don’t act alone. They interact with each other, sometimes reinforcing one another, sometimes canceling each other out, and sometimes changing how the cancer responds to treatment altogether. What looks like a simple list on paper is, in fact, a complex system.
A useful way to think about it is like a machine. If you look at one part in isolation, you might understand what that part does. But you won’t understand how the machine is working unless you see how all the parts move together. Cancer works in a similar way. The important question is not just which mutations are present, but how they interact and what that means for treatment.
Once you start looking at cancer this way, it becomes clear why interpretation is challenging.
A single tumor can involve dozens of genetic changes driven by:
Some may be important, others less so. Some may point to a treatment, while others may suggest that it won’t work. And the meaning of these findings can change depending on the type of cancer, the stage of disease, and the patient’s overall condition. On top of that, medical knowledge is constantly evolving. New studies are published all the time, and what is considered relevant today may change as new evidence becomes available.
In practice, this means that interpreting a genomic report is not a simple reading exercise. It is a process of putting pieces together, weighing different possibilities, and deciding what is most likely to matter for a specific patient.
Oncologists are trained to do exactly this kind of work. They review the data, consider the clinical context, and make treatment decisions based on their experience and the available evidence. Making sense of genomic data involves:
But there are practical limits. A genomic report can contain a large amount of information, and evaluating every possible interaction between different findings quickly becomes complex. In a clinical setting, decisions often need to be made efficiently. That means focusing on the most well-established and clearly supported options.
This approach is necessary, but it also means that some possibilities may not be explored in depth, not because they are irrelevant, but because they are harder to identify and evaluate manually.
When people hear about “deeper analysis,” it can sound abstract. In reality, it involves asking more detailed questions about the same data. Instead of looking at each mutation on its own, the focus shifts to how they relate to each other:
This is not about adding new information. It is about looking at the existing information more carefully and in a more connected way.
This is where computational methods can help. A computational approach, such as Genomate®, can examine many possible combinations of molecular findings at once. It can map how different pathways are affected and explore patterns that would be difficult to see through manual review alone. This does not replace clinical judgment. It does not make decisions on its own. But it can expand the range of what is considered and bring forward connections that might otherwise remain hidden.
In that sense, it works alongside the physician, adding another layer of analysis to an already complex process.
For patients, this helps explain a common experience: having a detailed report but still feeling uncertain about the next step. It also explains why different doctors may interpret the same report differently and why a second review can sometimes yield new insights.
More data does not automatically mean more clarity. The value of the test depends on how well the results are understood and applied.
Genomate focuses on this part of the process: the interpretation. Using computational reasoning, it analyzes tumor sequencing data as a connected system rather than a list of individual findings. It looks at how different molecular changes interact and what those interactions may mean for treatment.
The aim is to extract more meaning from existing data and identify treatment possibilities that may not be immediately obvious in a standard report. If you’d like to better understand your results, or confirm that nothing important has been missed, you can explore how a second opinion based on your existing data works ↗.
1. Why is genomic testing not enough on its own?
It identifies genetic changes, but it does not fully explain how those changes work together or what they mean for treatment. In some cases, a more detailed interpretation of the same data can provide additional clarity and help uncover options that were not immediately apparent.
2. What is the biggest challenge in precision oncology today?
The main challenge is making sense of complex molecular data and turning it into clear, practical treatment decisions. As reports become more detailed, the need for deeper, more systematic interpretation ↗ becomes increasingly important.
3. What comes after tumor sequencing?
After sequencing, the next step is careful interpretation, looking not just at individual findings, but at how they interact and what they may mean together. In situations where the initial report does not lead to clear answers, a more comprehensive second opinion ↗ review can help bring additional perspective.
.avif)
